Male or female adult asthmatics with mild to moderate persistent asthma.

18 to 45 (up to the 46th birthday) years of age.

Documented diagnosis of asthma at least 3 months prior to Visit 1, per NIH/NHLBI, EPR-3 criteria.

Able to withhold short-acting bronchodilators (e.g., albuterol or ipratropium bromide) for at least 4 hours prior to clinic visits.

Baseline FEV1 greater than or equal to 50% of predicted normal.

A Study of 2 Doses of MAP0010 in Adult Asthmatics